Protocol: (Give number and abbreviated title) Twoi.no. not to exceed 75 characters per line) 
Identification of Origin of Relapse in CLL Patients 
H Study Chairman: Albert Deiseroth, M.D. / Ph.C 
Patient Eligibility: 
(Twenty lines not to exceed 75 cherecters per line) 
l. 
Patients with CLL who have progressed following initial 
chemotherapy are not eligible for allogeneic bone marrow 
transplantation . 
2 . 
Age 16 to 6'0 years 
- 
3. 
Performance status 0-2 and 
and pulmonary functions: 
acceptable 
cardiac, renal, hepatic, 
treatment Plan: (Include dose adjustment) 
(Twenty lines not to exceed 75 characters per line) 
1. CLL patients will have peripheral blood and bone marrow stored 
after conventional dose chemotherapy. The autologous marrow 
will be purged in vitro following which 30% of it will be 
marked with the GIN safety modified retrovirus after CD34 
positive selection. 
2. Autologous bone marrow reinfusion on day 9. Thirty percent of 
the autologous bone marrow cells stored will have been exposed 
to a replication incompetent retroviral vector, which is 
designed to mark the hematopoietic stem cells from the normal 
and leukemic population. Benadryl 25 mg and solucortef 100 mg 
will be given before bone marrow infusion to prevent 
anaphylaxis . 
3. Patients will receive prophylactic oral antibiotics and blood 
products irradiated with 2500 rads. 
Recombinant DNA Research, Volume 16 
[387] 
